全文获取类型
收费全文 | 6542篇 |
免费 | 272篇 |
国内免费 | 208篇 |
专业分类
耳鼻咽喉 | 144篇 |
儿科学 | 150篇 |
妇产科学 | 237篇 |
基础医学 | 250篇 |
口腔科学 | 123篇 |
临床医学 | 420篇 |
内科学 | 929篇 |
皮肤病学 | 126篇 |
神经病学 | 360篇 |
特种医学 | 195篇 |
外科学 | 1593篇 |
综合类 | 724篇 |
预防医学 | 245篇 |
眼科学 | 93篇 |
药学 | 326篇 |
1篇 | |
中国医学 | 113篇 |
肿瘤学 | 993篇 |
出版年
2024年 | 2篇 |
2023年 | 94篇 |
2022年 | 282篇 |
2021年 | 323篇 |
2020年 | 264篇 |
2019年 | 369篇 |
2018年 | 311篇 |
2017年 | 243篇 |
2016年 | 213篇 |
2015年 | 203篇 |
2014年 | 479篇 |
2013年 | 397篇 |
2012年 | 411篇 |
2011年 | 384篇 |
2010年 | 338篇 |
2009年 | 307篇 |
2008年 | 328篇 |
2007年 | 312篇 |
2006年 | 286篇 |
2005年 | 228篇 |
2004年 | 168篇 |
2003年 | 132篇 |
2002年 | 97篇 |
2001年 | 88篇 |
2000年 | 101篇 |
1999年 | 57篇 |
1998年 | 48篇 |
1997年 | 35篇 |
1996年 | 36篇 |
1995年 | 18篇 |
1994年 | 24篇 |
1993年 | 16篇 |
1992年 | 14篇 |
1991年 | 11篇 |
1990年 | 4篇 |
1989年 | 8篇 |
1988年 | 12篇 |
1987年 | 5篇 |
1986年 | 4篇 |
1985年 | 50篇 |
1984年 | 64篇 |
1983年 | 40篇 |
1982年 | 57篇 |
1981年 | 53篇 |
1980年 | 28篇 |
1979年 | 29篇 |
1978年 | 16篇 |
1977年 | 19篇 |
1976年 | 10篇 |
1974年 | 2篇 |
排序方式: 共有7022条查询结果,搜索用时 15 毫秒
1.
2.
3.
《Cirugía espa?ola》2022,100(11):709-717
ObjectiveMost evidence, including recent randomized controlled trials, analysing anal squamous cell carcinoma (SCC) do not consider immunocompromise patient population. The aim of this study was to compare clinical and oncological outcomes among immunocompetent and immunocompromised patients with anal squamous cell carcinoma.MethodMulticentric retrospective comparative study including 2 cohorts of consecutive patients, immunocompetent and immunocompromised, diagnosed with anal SCC. This study evaluated clinical characteristics, clinical response to radical chemoradiotherapy (CRT) and long-term oncological results including both local and distant recurrence, overall survival (OS) and disease-free survival (DFS).ResultsA total of 84 patients, 47 (55.6%) female, diagnosed with anal SCC from January 2012 to December 2017 were included, 22 (26%) and 62 (74%) patients in immunocompromised and immunocompetent groups respectively. Patients in immunocompromised group were significantly younger (53 vs. 61 years; P=0.001), with smaller tumoral size (P=0.044) and reported higher rates of substance abuse.including tobacco use (P=0.034) and parenteral drug consumption (P=0.001). No differences were found in administered therapies (P=301) neither in clinical response to chemoradiotherapy (83 vs. 100%). Moreover, similar 5-year OS (60 vs. 64%; P=0.756) and DFS (65 vs. 68%; P=0.338) were observed.ConclusionThe present study shows no significant differences in long-term oncological results among immunocompetent and immunocompromised patients diagnosed with anal SCC, with a similar oncologic treatment. This evidence might be explained due to the close monitoring and adequate therapeutic control of HIV positive patients. 相似文献
4.
5.
贺利平 《实用中西医结合临床》2022,22(14)
目的 探讨胆囊结石合并胆总管结石(CBDS)术后患者复发情况及危险因素。方法 纳入114例2019年1月~2020年12月在本院行ECRP联合LC治疗的胆囊结石合并CBDS患者,回顾性分析其临床资料,根据所选患者ECRP联合LC术后随访1年内是否复发(REC)将其分为REC组(32例)和未REC组(82例)。回顾性统计胆囊结石合并CBDS术后患者REC情况,比较REC组和未REC组的临床资料,并分析胆囊结石合并CBDS术后患者REC的危险因素。结果 114例胆囊结石合并CBDS术后患者REC32例,发生率28.07%。胆囊结石合并CBDS术后患者REC的危险因素为胆道感染、胆道口括约肌切开、术者经验≤3年、胆道括约肌功能障碍(OR=4.170、4.047、3.568、3.367,P<0.05)。结论 胆囊结石合并CBDS术后患者REC的危险因素与胆道感染、胆道口括约肌切开、术者经验≤3年、胆道括约肌功能障碍密切相关,可据此针对性制定临床治疗及护理干预措施方案,以降低胆囊结石合并CBDS术后患者REC率。 相似文献
6.
《Anais brasileiros de dermatologia》2021,96(5):602-604
Diffuse cutaneous leishmaniasis is a rare universal disease associated with an inadequate host cell immune response, caused by different species: infantum, aethiopica, major, mexicana, and others, which presents the challenge of a poor therapeutic response. In Brazil, it is caused by L. amazonensis. A case confirmed by histopathology with an abundance of vacuolated macrophages full of amastigotes and lymphocyte scarcity, identified by RFLP-ITS1PCR and in vitro decrease and exhaustion of the host cell immune response to L. amazonensis antigen, was treated early (3 months after the onset) with Glucantime (2 months) and allopurinol (29 months) with clinical cure, after a follow-up for 30 months after treatment. 相似文献
7.
《Clinical colorectal cancer》2022,21(2):80-88
Lateral lymph nodes in low, locally advanced, rectal cancer have proven implications for local recurrence rates, which increase drastically in the presence of persistently enlarged lateral lymph nodes. These clinical implications warrant a thorough understanding of lateral nodal disease with awareness and knowledge from all three specialties involved – radiology, radiation oncology, and surgery – to ensure proper treatment. Relevant literature for each specialty, including all current guidelines and perspectives, were examined. Variations in definitions and treatment paradigms were evaluated. There is still no consensus for the standardized treatment of lateral nodal disease. Each discipline works according to their own available evidence, but relevant data are scarce. Current international guidelines and standard recommendations for the diagnostics and treatment of lateral lymph nodes are lacking. This results in differing perspectives and interpretations between the disciplines which can lead to challenging communication in an area where multidisciplinary collaboration is essential. This review addresses this by presenting the current evidence, perspectives and practices of each specialty and makes suggestions for each phase of the diagnostic and treatment process for patients with lateral nodal disease. By doing this, steps are taken toward achieving international consensus, and multidisciplinary collaboration. 相似文献
8.
9.
10.
《Clinical genitourinary cancer》2022,20(3):e217-e226
Background: Intraductal carcinoma and cribriform (IDC/C) tumor features are well-established prognosticators of biochemical recurrence (BCR), metastasis, and prostate cancer (PCa)-specific mortality. However, approximately 70% of PCa patients undergoing a radical prostatectomy are IDC/C negative, yet up-to 20% of these patients progress and experience BCR. Thus, tumor histopathologic characteristics such as IDC/C alone are limited in their ability to predict disease progression. Conversely, several nomograms such as Cancer of the Prostate Risk Assessment-Surgery (CAPRA-S) have been developed to aid in the prognostication of BCR, but not yet widely applied in clinical settings. Materials and methods: In this study, we assessed the combined prognostic utility of IDC/C, and CAPRA-S for BCR in 3 PCa patient cohorts. Results: CAPRA-S+IDC/C improved the predictive accuracy of BCR in all 3 cohorts (P < .001). Specifically, among IDC/C negative cases, CAPRA-S improved the prognostication of BCR in low-risk (Cohort 1; P < .001, Cohort 2; P < .001, Cohort 3; P = .003), intermediate (Cohort 1; P < .001, Cohort 2; P = .006, Cohort 3; P = .03) and high-risk (Cohort 1-3; P < .001) patients. Conversely, IDC/C improved the prognostication of BCR among CAPRA-S low-risk (Cohorts 1; P < .001 and Cohort 3; P = .003) patients. Conclusion: Our results suggest the investigation of histopathological IDC/C features in CAPRA-S low-risk patients and conversely, nomogram CAPRA-S among IDC/C negative patients improves the identification of patients likely to experience BCR, which would otherwise be missed through current assessment regimens. These patients can be offered more intensive monitoring and adjuvant therapies upfront to circumvent the development of recurrent cancer or overtreatment at the time of surgery. 相似文献